Gad Cotter MD, FACC, FESC President and CEO Momentum Research, Inc. 3100 Tower Boulevard, Suite 802 Durham, NC 27707 Ph: 919-287-1824 x 307
Dr. Cotter received his undergraduate degree and medical degree from Hadasah School of Medicine at Hebrew University. Over the next eleven years he completed his internship, residency, Cardiology fellowship and served five years in the Israel Defense Forces. He currently is an Assistant Professor of Medicine at Duke University Medical Center. His clinical and research interests are the development of new therapies for acute and chronic heart failure, the role of neurohormonal activation in acute heart failure, the role of post traumatic stress disorder in patients with ischemic heart disease and congestive heart failure and in exploring the role of hemodynamic measurement and cardiac power in patients with acute and chronic heart failure. Dr. Cotter is the author of multiple peer-reviewed manuscripts, reviews, book chapters and editorials on cardiovascular disease, acute and chronic heart failure and the clinical utility of multiple types of hemodynamic measurements used in the treatment of acute heart failure. He has participated in multiple global, multi center cardiology clinical trials in all phases I-through 4, registry trials and NIH funded trials as Principle Investigator, Operational Leader and National Leader. He has strong expertise in developing operational methods that are effective in Europe, Russia and Israel as well as North America. Throughout his extensive clinical research experience he has consistently promoted the use of practical, innovative operational methods to a ensure clinical trials are done on time and within budget. Dr. Cotter has served as a consultant and on advisory boards to Actelion Pharmaceuticals, NovaCardia Inc, Cytokinetics Ltd and Biohart Ltd. In addition, he is a member of the working group on clinical pharmacology of the European Society of Cardiology and a Fellow of the American College of Cardiology. He is a member of the editorial board for the European Journal of Heart Failure and the Journal of Cardiac Failure.
1. Kaluski E, COTTER G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reisin L, Zimilichman R, Vered Z. Optimization of Bosentan Dosing in Patients With Severe Systolic Dysfunction Associated with Secondary Elevated Pulmonary Artery Pressure. Cardiology 2007 (In Print)
2. Cotter G, Felker GM, Adams KF, MILO-COTTER O, O’Connor CM. The pathophysiology of AHF – is it all about fluid accumulation? Am Heart J. 2008 Jan; 155(1):9-18. Review.